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My capstone project anaJyzes the crisis of retirees on a fixed income due to high pharmaceutical costs.

I hoped

to

prove that the opinion that there exists a state of crisis that is being popularized by politicians

and the media is really just existing at the individual level rather than a widespread epidemic. I believe that
the "crisis" is being exploited for political gain, as there can be painted a clear "good guy/bad guy"
situation, with the phannaceutica1 companies being the latter. Additionally, the AARP-age group is a strong
supporter to have on one's side in politics. Politicians arc playing

to

this fact and arc proposing policies that

disregard the economic repercussions that will surely be suffered through their attempts to cap prices and
restrict the pharmaceutical industry. In their efforts to win support from this influential group of aging
Americans they will, in the end, harm them.

For my literature review, I have chosen thirteen articles on the topic of drug costs and their effect upon the
elderly. The majority of these articles review the current political climate and the propositions before our
government to rectify the skyrocketing costs of prescription drugs.
Of the thirteen articles, twelve take the stance that those on a fixed income arc suffering. They arc the
most in need, thus, those most affected. The pharmaceutical industry comes out looking the greedy, bad
guy, and there must be legislation put in place to regulate their actions. Each article; however, puts a

different twist on the information, with some siting failings of statistics, others looking at specific diseases,
etc. They differ enough from each other to keep the reading both interesting and insightful.
There is one piece; however, which takes on an entirely different viewpoint on this situation, "Our
phoniest drug war," by Doug Sandow. This article made this assignment all the more interesting. After
reading and reviewing one dozen articles which presented the same problems, arguments and conclusions, I
got to lucky number thirteen - a relatively short piece which makes the bold statement, "there is no crisis."
The following is a summary of each piece:
I.

"How Medicare beneficiaries payf
or prescription drugs"

This article outlines the sources of the crisis of drug costs and the elderly.
For retirees, most health benefit supplements come from employer-sponsored health plans. These
generally impose steep co-pays for prescription drugs. The percentage of employers offering any retiree
benefits is steadily declining, and those remaining are requiring that retirees pay a substantial part of their
premium. Many of these employers are also requiring that retirees sign up for the Medicare+ Choice plan,
which is very restrictive in their drug coverage. Still others "carve-out'' drug benefits, offering them at a
separate premium. Those retirees with no employer program can purchase the Medigap supplement to
Medicare, where prescription benefits carry a high deductible and copay as well as a benefit cap. The
elderly poor rarely have employer-sponsored benefits and cannot afford to purchase Medigap policies; however, Medicaid is available to those who qualify.

There exists a real problem for those who lose or try

to switch coverage, falling into a gap ofno coverage at all. Coverage has proven to be very unstable.
The article goes on to provide Web sites that provide useful information on coverage, such as "Medigap
Compare," and "HFCA."

2. "Restricting drug choice can increase health care usage"

This article presents the findings of a survey conducted at the Institute for Clinical Outcomes Research of
the School of Medicine, University of Utah, regarding prescription spending.
The questions asked were not new ones: "who spends more, younger or older patients, for what ailments
and generic versus high cost."

The conclusions presented were not unexpected: younger patients spend

less and on fewer prescriptions per year. Of the studied diseases, arthritis, heart disease, etc., the elderly
received more prescriptions. It was also concluded that if access to drugs were limited, the elderly would be
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more affected, except in the case of asthma. The study also found that increased usage of generic drugs
resulted in even higher costs among the elderly. Generics use is not cost-containment appropriate for the
elderly.
This last conclusion was the one I found most interesting; however, neither the article nor the study
explained why generics caused higher costs. Th.is would have been a fresher point to elaborate upon, since
generics are traditionally used to cut costs. Why does this fail in this age group?
The use of generics will be discussed again later in my review.

3. "Drug pricing

"powder keg" stirs u
p US health-care politics"

Th.is piece looks at both sides of the pharrnaceutica1 cost argument.
The phannaceutical industry contends that its products are a "wondrous bargain, well worth their rising
prices because of the therapeutic benefits they confer for conducting costly research for even better drugs."
The consumer and political sides argue that the costs are a burden on needy patients.
The author sites a study by the Library of Congress that finds that due to tax breaks, after-tax profits for
the phannaceutical industry averaged 17% of sales, while other industries weighed-in at just 5%.

The

industry defends itself against this finding, stating that these tax breaks are received because they invest
heavily in much-needed research and development.
The industry is fearful, says the author, of the inevitable price controls and rising antagonism towards
them. The elderly are the hardest hit by the high prices, but they are politically well organized, and arc
"courted by office- seeking politicians."

4. "Editor's PicK'
This piece asks the questions:

"ls there a maximum amount of profit that companies should earn?"

And, "Should our elderly, the most medication-dependent sector of society, be held hostage to corporate
greed?"

Its answer is to blame drug companies for creating unnecessary demand for their products through direct
to-consumer advertising. "$905 million was spent by the industry in the first half of 1999 alone, up 43'/o
from the prior year." The author contends that these ads change the physician-patient relationship, creating
fear and demand in the patient, who in turn demand the prescription from their doctor. Rather than argue,

the doctor usually complies.
Do these ads empower the patient? Are they a consumer service as argued by the industry? The author

does not support this defense, and believes that urgent action is needed to curtail this excess of the drug

industry.
This is an interesting approach, I think, to blame advertising. My question after reading this article is, how
does this differ from any other industry that puts a commercial on TV in order to influence perspective

3

customers? I personally cannot sec why any industry docs not have the right to promote their product via
mass media.

5. "Bitterpil/s"

This article sites the statistic that one in three seniors have no drug insurance. It goes on to say that in the
US, prescription costs arc the highest in the world - nearly twice what Europeans and Canadians pay for
the sune drugs.

Drug makers claim that prices have risen due to several factors, such as: new medications are
''breakthrough" drugs which arc helping people to live longer; the number of years it takes to bring a drug
to the market; due to price controls abroad, they arc forced to make up the difference in this country; the
increase in outpatient services, where most policies do not cover prescriptions as opposed to inpatient care
where these same drugs are covered.

The industry believes that drug prices have become a political topic, as it is easy to exploit the "good
guy- bad guy" scenario in this issue, and that possible drug-price cutbacks will take their toll on research,
especially in rare diseases. They also f
ear that federal dollars used to fund drug benefits will mean cuts
elsewhere in healthcare, as federal funds are finite.

Much like in the article presented, "Editor's Piclc," this piece also places blame upon the rising awareness
of patients due to direct advertising by the pharmaceutical industry. New Zealand and the US are the only
nations that currently allow such advertising.

6. "Prescription drug spending: T
he impact o
f age and chronic disease status"

The authors here open their piece with this statistic, which sums up the nature of the elderly- drug cost
crisis:

"... The elderly account for 34% of total phannaccutical. expenditures, although they make up 12% of
the population," and they further conclude that, "significant pharmaceutical spending is for the treatment of
chronic conditions ... "

Chronic disease is the most important detenninant of drug expenditure. Among the elderly, 36%, state the
authors, had three or more chronic conditions and accounted for 57% of drug spending by this age group.
Of these conditions, arthritis and hypertension arc the most common. The highest spending is for the
treatment of diabetes, emphysema, and heart disease.

The findings of the authors also show the importance that outpatient services have upon expenditures. The

data also indicate how drug use is distributed nationally by therapeutic class. Additionally, they've found
that patients arc more responsive to increases in drug prices as they affect their budget more and this causes
changes in behavior. This infonnation can be used selectively in benefit design.
In general, I found the conclusions presented by this study confusing and difficult to understand. The data

on therapeutic classes and cost shifting were not made clear enough to the reader.
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7. "Prices, patients, risks and research"

".... the appearance of expensive new therapies is dividing the population into the "haves" with insurance
coverage of prescription drugs and the "have nots" .... " Many seniors, the author points out, fall into the

"have nots." This f
act is putting pressure upon Congress to provide Medicare, outpatient drug benefits.

Much like the earlier reviewed article, "Drug-pricing powder keg," this piece argue5 that price regulation

will take its toll on research and development, thus hurting these same consumers in the end.

The article goes on to describe various plan options, such as "catastrophic" plans which target chronic and
specific diseases only, incremental approaches, and broad plans with copays and deductibles. A major

problem, as pointed out by the author, is that these plans will increase government influence over prices.

Additionally, manufacturers would be under pressure to get on "preferred lists" of formulae.

There is also the problem with generics, where the government is pressuring the FDA to approve these

lower-cost drugs faster. However, if we go back to the earlier -reviewed article, "Restricting drug choice

can increase health care usage," the authors there concluded that generics do not contain costs for the

elderly. If you take this as f
act, this government measure will not help the group it is intending to relieve.

The FDA, in tum, is actually seeking to increase their efforts to reduce risks and improve quality in drugs,

including generics, by tightening their standards of evolution. They are taking a "safety first" approach,

which the author supports. They are also seeking to protect consumers from less-expensive Internet

purchasing, where product quality is questionable.

8. "States' Rx/or drug costs"
In this piece, the author explores how different states arc working to curtail the hardships placed upon the

elderly by increasing drug prices.

The opening statement illustrates the crisis, as it describes a 67

year-old women who has had to return to work in order to pay her $469 per month ulcer medication

bills. Another story is of a Florida rctircc who spends nearly one-half of her yearly-fixed income on her
prescriptions for a lung ailment. Florida offers no drug-coverage plan.

An example of one state that is working to ease such suffering is Maine, where the "Low Cost Drugs f
or

•
Toe Elderly'' program went into effect in 1999, and now pays 800/e of the costs for those in need. Maine has

the nation's first law that includes price controls on prescriptions. Maine also created the "Maine Rx"

program which allows any resident without prescription coverage to purchase drugs at a discount, which is

based upon Medicaid rates. However, this program has been challenged in court by the pharmaceutical

industry and could set precedent for programs in other states.
As of December 1999, 16 states had some fonn of drug assistance for seniors. By 2000, this had

increased to 22. Other states, such as Iowa and New Hampshire, have initiated buying "clubs" offering a

discount These subsidies are being funded by tobacco-settlement funds. Maine, New Hampshire, and

Ycnnont has instituted ajoint "pharmacy - benefits manager," who will create educatiom,.J
programs for doctors and patients in cost effective medical regimes. The author points out that such state

programs are costly and that this is preventing many states from setting up similar state-funded plans. Many

s

opponents believe that this issue is not one that should be dealt with on a state level and must be a federal
one, siting that a "patchwork" of state plans will create chaos in the phannaccuticaJ industry.
I found this article quite informative. Instead of painting a11 of the negatives and crises, it presents various
positive approaches which the states arc attempting. The sidebars also do a fine job of summarizing various
state's actions.

9. "Persistence o
f use o
f lipid-lowering medications: A cross-nationa/ study"

When I came across the title of this article, I thought it was about a specific medical study, rather than an
investigation into drug/price effects on the elderly. As I read on; however, I found it a piece useful to my
review, because it shows how patients failed to continue their regiment of lipid-lowering medications due
to the costs involved. It additionally shows how their health suffered because of this. These lipid-lowering
drugs arc used by patients at the highest risk for cardio-vascular disease, namely the elderly, poor and
minorities. This piece is the best illustration of the crisis of prescription costs and the elderly that I've come
across, as it is very specific, showing the regiment necessary to maintain health and the effects caused by
disruption in this regiment.
The studies were described fully, coming to the conclusion that the lower the income level, the higher the
rate of noncompliance. The data were adjusted for such contributing factors as side effects and
inconvenience. In fiscally generous insurance systems, compliance was highest. The more cost out-of
pocket, the lower the compliance.

10. "The price isn't right"

This article makes an interesting opening statement," ... astronomical prices arc rooted in govemment
funded research, necessitating that government policy needs to bring prices and research priorities
down to earth."
The author explains that private-sector labs claim to be responsible f
or breakthroughs in drugs. This is
their great defense - limit prices and you will "short circuit the current medical revolution." But, this

defense falls short. The author states that every independent study that investigates sources ofmodical
innovation comes to the conclusion that it is public-sector research, not private, which has lead to the

majority of significant advances. To support this, the author tells the story of a boy with Gaucher disease, a
genetic disorder. The price of treatment of this ailment is nearly one quarter of a million dollars per year.
The technology to treat this is government developed, from the National Institutes of Health. The
government; however, transferred the intellectual property to a private company, which now produces the
treatment. And, this scenario is not a unique one.
A 1997 National Bureau of Economic Research study showed that public research led to 15 of the 21
drugs considered having the highest therapeutic value introduced between 1965 and 1992. The same
study also found that 60% of 32 innovative drugs would not have been discovered or would have taken
longer to discover without research contributions from government labs and noncommercial institutions.
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In other words, it is the taxpayer that is funding research, not the pharmaceutical manufacturers. In

f
act, the author says, most of the research by private labs is aimed at stealing marketshare from competitors
or replacing their own products coming off patent.
The author blames the government's inability to track tax-payer funded research, and adds that if the

government was to increase public funding of research, they could control prices without the f
eared effects
on research and development.
I found this article extremely interesting. Much of my other reading speaks of the industry defense
concerning research and development, but this author completely tears that apart, putting research
funding in a whole new light. That's precisely why I chose this article for review.

11.

"Prescription drugs and the elderly: Issues and options"

This article states many of the points of crisis and the supporting statistics that my other article choices
used to describe the problem of drug costs and the elderly.

I feel no need to review those again; instead,

focusing on the public policy options presented by the author.
If prescription drug coverage for the elderly were to be extended, there arc issues that need resolution,
namely, "Who?" "What?" and "Who will pay for it?'' The author outlines four policy options to answer

these questions.
a.)

Encourage state pharmaceutical assistance programs. Offering matching grants will encourage more
states to develop assistance programs for those not covered by Medicaid. The advantage is that it
could be targeted at the lowest-income elderly and would allow state discretion. The disadvantage is

that both the federal and state governments need to find funding for this program.
b.)

Require all Mcdigap policies to cover prescription drugs. The advantage here is that it will eliminate
the possibility of adverse selection, assuring fair, stable benefits. The disadvantage is that this will

not cover the elderly without supplemental coverage.

Also, th«e exists no contnbution to cost

containment.
c.)

Extend Medicare benefits to cover prescription drugs while reducing the deductible to a more
affordable level. The advantage is that enrollment could be more universal and that the concentrated
market power of Medicare could be used to contain costs. The disadvantage is that it could lead to
redistribution of income from those who have coverage to those who don't Also, it will substitute
public financing for private.

The author concludes that there needs to be a better understanding for more infonncd debate before any

options can be chosen.

12. "Making sense o
f dru
g prices"

In this article, the author makes and defends the following statement:
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"Any form of price regulation, including the setting of uniform prices within the United States or cross·
nationally, would discourage innovation and competition. The best way to make drugs more affordable for
the elderly would be to allow them to choose among competing private sector plans."
The author contends that studies that present drug price as higher in the US than other countries arc
flawed. First, because the study samples include only leading branded products and did not consider

generic substitutes. Second, the studies did not account for volume discounts in the US. And, third, because
arithmetic averages were calculated using unweighted averages. If these items were corrected, the author

believes studies would show that US drug prices arc f
ar from the highest in the industrialized world.
It is also suggested that studies of domestic prices arc flawed as well. The House Committee on
Government Reform and Oversight reached misleading conclusions, mainly because they compared retail
prices to Federal Supply Schedule prices. These prices arc at "different levels of the distribution chain,"
and cannot be fairly compared, as the FSS involves favored.customer discounts.
Another misconception involves proposed plans that will offer a discount to elderly customers. If
discounts were to be given to elderly cash -paying customers who do not participate in a managed
program, how would it be done? Since they purchase directly from a pharmacy, manufacturers would have
to provide the pharmacy with a discount. There is no assurance that these discounts would then be passed
along to customer.

Going back to the opening quote, the author believes that competition would be the best answer to the
elderly problem. Customers could select programs based upon their preferences and cur-of-pockee costs.
Competition would regulate the prices. It is concluded that rather than focus on the profits of
pharmaceutical manufacturers, we would be better served looking at laws, regulation and taxes that would
encourage healthy levels of research and development investment.

13.

"Ourphoniestdrugwar"

This article describes the "lack" of a problem with drug prices. The author goes as far as to say, ''There is
no crisis."

"The biggest complaint about prescription drugs is the cost, even though Americans devote more money
to alcohol and almost as much to tobacco." This statement sums up the attitude of the author.
He sites analysts William Orzechowski and Robert Walker, saying that 70% of the elderly spend less than
$.500 per year on pharmaceuticals and only 4% spend more than $2,000 per year. Also, that two-thirds have
some sort of coverage f
or pharmaceuticals.
He agrees that phannaceutical spending has increased, but that this had lead to the mispcrccption of
runaway prices. The increase, he explains, is in total outlay, not average price. Government estimates arc
flawed due to poor sampling, ignoring generics, falling new-drug prices, and drug quality.
The author goes on to blame the FDA regulations for as much as doubling the cost of new drugs. He adds
that any new drug policy would inflate demand and spending and lead to price and use controls.
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It is concluded that the government should "do no harm." By destroying the phannaccutic:al industry, no
one would get financial relief.
While I'm not sure I can agree with the positions taken by the author, the article does make me question
the current state of drug costs on the elderly and the propositions before government to correct the
situation.

This author and his stance is most in line with the stance that I have taken on this issue, that there

docs not exist a wide spread crisis and reigning in the pharmaceutical industry will serve no one.

In conclusion, after looking at the summaries of these collected readings, it is evident to me, with the
exception of the last piece, that the authors believe something must be done to aid the crisis of drug costs
and the elderly. It is debatable how dire the actual crisis is, as the data available is believed to be flawed.
Each article presents different causes and different options to correct the problem, but there exists
agreement that those currently before Congress arc under too much outside influence to be properly
designed. Options will have negative repercussions if great care isn't taken in their design. Policy cannot
serve all parties.
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To support my stance on the issue of drug costs and those on a fixed income, my chosen methodology was

to first administer a survey to the group in question, namely retirees. This would give me a good statistical
basis to prove or disprove my point I also sent out interview-type questionnaires to subjects functioning in

different arenas in healthcare, namely healthcare provider, pharmaceutical representative and elected
officials from the sample community. This would provide an opportunity to compare and contrast the
beliefs and attitudes of these varying subjects.
In May of 2001, I met with the Cedar Grove New Jersey Senior's Club to administer a survey discussing
the problem retirees on a fixed income face regarding the high cost of prescription drugs. I chose this group
because all members must be over 55 years old and retired. They are aJso members of one geographic
community, which is for the most part typical of suburban New Jersey. By administering this survey, I was
hoping to establish the level of"crisis" that existed within this community regarding their situation with
high drug costs. A copy of this survey can be found in Exhibit 5.
Cedar Grove, where this sample was taken, is a small suburb of 11,731 people located in Northern New
Jersey. Those 65 years and older account for 21.23% of it's population. Nearly 95% of the population is
white. With a median household income of over $55,000 and only 332 persons living in poverty, it could be
said that this town is moderately affluent. It should be noted that Cedar Grove is home to a county hospital
where many of those labeled as impoverished reside. A table of demographics is provided in Exhibit I.

Of the 90 surveys administered, 62, or 68.89% were returned.

The questions focus upon the medical

history of the participants and the type of coverage they hold, as well as the personal affect drug costs have
had on their lifestyle. The participants were instructed too not respond to questions that they felt invaded
their privacy or made them feel uncomfortable.

Of those sampled, the average age was 75 years old. 68% were female and 32% male. The average length
of residence was 36 years. The average rate number of years retired was just over 12.
In looking at these statistics along with my observations from our meeting, I would say that the majority
of the sample were outgoing and involved and had lived in the community long enough to establish a
support network of friends. I believe this important because these people were not isolated, but active
members, as opposed to being homebound and of poorer health, which would have skewed the data.

The first question concerning health asked, "For what conditions do you regularly take prescription
medication?" This question was trying to establish the routine involved with the sample's prescription costs.
The results are illustrated in Exhibit 2. The majority, at 41 %, regularly take drugs for high blood pressure.
This was followed with 21 % for "Other." The majority of conditions listed under "Other" were for

JO

cholesterol and thyroid related conditions. Heart conditions (I 7%), glaucoma (5%), diabetes (4%) and
depression (3%) followed these.

The next question assessed the general health of the sample, by asking what chronic diseases they suffer
from. This response is illustrated by Exhibit 3. The majority, at 30%, suffered from heart conditions. This
was followed closely by arthritis at 26%. The remaining disorders were cancer (I 5%), respiratory ailments
(13%), other (8), stroke (5%) and glandular (3%). The "Other" consisted of disorders such as reflux and

aneurysms.

The next group of questions centered on the sample's insurance coverage, in an effort to illustrate how
much coverage the group had, why they chose their plans and the costs involved. It also looked for lapses
in coverage, such as too few participants holding MediGap policies.
When asked if they canied traditional Medicare or HMO's, a large majority, 86%, participated in
traditional Medicare. When citing their reasons for this, most replied that they distrusted HM O's, and that
they wanted freedom to choose their own physicians. Most of those who chose HMO have cited their
reason as being that this was the plan provided by their employer upon retirement.

Many did not like the

fact that HMO's did not allow a patient to choose their own physicians.
Perhaps, due to the ages of the participants, they have had little experience with HMO's, as they are a
relatively new choice. Their feelings of distrust and unreliability may stem from this, as well as dislike of a
system that places restrictions on their care. The younger generations are more comfortable with HMO's as
they have been raised in a culture that supports their use.
When asked if they carry a McdiGap policy, 53% stated that they did not. Of the 47% that did cmy this
coverage, the average price paid per month was $96. It is important to note that many of the participants
with MediGap received it free or substantially subsidu.od as part of their retirement package, thus skewing
the results.

If these outliers are removed, the average monthly price paid is $127. The main reason cited for

carrying this additional coverage was that it supplements Medicare. For those on a fixed income, coverage
at this price could be difficult to afford, and the f
act that nearly half of the sample did carry it was
surprising. I expected that fewer could afford it's high premium.

The final group of questions asks about the choices made and hardships endured due to the cost of
prescriptions. The results can be reviewed in the graph in exhibit 4.
The first question asked, ''Have you ever not filled a prescription due to its cost?" 85% of the sample said

''No."
The second question, "Have you ever rationed your medication to make your prescriptions last longer?"

was answered "No" by 8'1°/t of the sample.
The results of the third question were similar, "Have you ever postponed paying bills or reducing f
ood
outlays due to the cost of your medication?"

94% said ''No", they have not.

II

Those who answered "Yes" to these questions were obviously in the vast minority; however, in a town with
this level of affluence and in a group with this level of insurance coverage., the f
act that there were those

who do have to make these sacrifices in order to pay for their medications was surprising. One of the
participants added commentary to their answers, stating that ... "although they themselves had no problems
associated with their prescription costs, that they knew of others in the community who did, and they felt it
was a disgrace and wanted something done to prevent this from happening."

I was very satisfied with the results of this survey. I felt the conclusions derived at from the sample
provided great insight into the state of"crisis" regarding prescription drug costs. The participants were
more than willing to be a part ofmy study, leading me to believe that politicians should go to their
constituents more often before fonning their own opinions on this topic. Perhaps then any legislation
presented and/or voted upon would be better designed and more serving of all parties involved.
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For the next part ofmy analysis of the effects of prescription drug prices, I looked to the various articles
that I presented in my literature review. Ofthe thirteen, all asked essentially the same questions; yet,

depending upon the point of view of the author took different stances. Is there or is there not a crisis? Who
caused the crisis? Will price cap policies do more harm than good'? And, what should a federal policy

include?

I prepared a questionnaire/interview using these four questions, then presented them to six interviewees,

each coming from a different arena. The aim was to compare the responses of each for differing opinions

based upon their participation in Healthcare. By looking at the varying perspectives, I was searching for

any agreement on the issues, as well as looking to see how differing arenas influence these opinions.
One questionnaire went to a representative of the pharmaceutical industry, Ms. Yolanda Burdsy, Quality

Assurance Specialist The second went to Dr. Veronica Santilli, practicing physician, President of a large

pediatric practice and member of the Board of Empire Blue Cross Blue Shield. The third went to a
healthcare administrator, Dr. Raul M. Abad, Vice President of Medical Affairs for Easton Hospital in

Easton, Pennsylvania. For the last group of three, I thought it important to get the opinions of elected

officials that represent the geographic sample. As political figures, it is this group who could at some point

be voting on actual legislation regarding drug policies. One went to the Town Council of Cedar Grove and

was answered by the Mayor's Office, another went to Acting New Jersey State Senator Kevin J. O'Toole,

and the last was sent to the offices of House Representative Bill Pascrell of New Jersey who also represents

Cedar Grove. Their responses are as follows:
Looking first to Yolanda Burdsy- Pharmaceutical Quality Assurance Specialist
1. Do you believe that there does or docs not exist a state of crisis regarding prescription drug prices and
their effects upon those on a fixed income? Why or Why Not?

Although it is no surprise thaJ drug prices are progressively increasing due to many driving
factors in the changing paradigm o
f hea/thcore delivery a state o
fcrisis is trul
y a concept thaJ
may be defined accordingly through the eye o
f the beholder.

The e
ff
ec
to
fsharply rising drug

prices upon those individual withftxed income may be q11ite devastating. However, governments
that impose price controls and other market interventions delay research and limit access to new
drugs and therapies; and

ifcomwners throughout the world remember that governments which

impose price controls are not getting what they bargainedf
or they will put into perspective that an
increase in drug price is necessary to facilitate the research, production, and distribution that is
needed accordingly.

In addition government:r aren't achieving the long term savings they ho
ped

for andpatients are often denied access to the newest drugs f
or years after they are available to
the rest o
f the world Yes many individllals existing and surviving on limited means financially
may view this paradigm in a crisis mode however, these price hikes ore warranted

2. If "Yes, you do believe there exists a crisis," what do you believe is the main contributor, the
Phannaccutical industry seeking to maximize profits, or the current lack of a Federal policy to regulate
prices?

In my eyes the main contributors that have driven this crisis into existence during this ero o
f
healthcare delivery are rotes o
fgrowth in pharmaceutical spending in many markets with
widespread interventions have been no different from those in markets with few so why decrease
the source o
fprofitable funding?
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Secondly widespnad access to new drugs f
or widely under-treaJed conditions such as heart
disease and depression have been delayed in many countries thal have priu control policies in
place.

3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon
Pharmaceutical industry investment in rcscarch and development? Why or Why Not?

Yes I believe that policies that impose caps on prescription prices will have negative
repercussions upon the pharmaceutical industry irrvestment in research. developmenl and twerall.
For example, Japan, which has severe mark.et restrictions, has less access to new medical
therapies than any other G-7 nation. O
f the 230 newpharmaceutical products launched around
the world since 1985, more than halfare not available in Japan. In the United Kingdom, stat ins,
an important new weapon in the fight against high cholesterol and heart disease, areprescribed
Jess lhan hal
f as often as they are in the United States.

4. In your opinion, what is the single most important item a government policy on prescription drug prices
must contain?

The adoption o
f policia that encourage research into newproducts but control health care costs
in the Jong run is a crucial component to incorporate within the government policy on prescription
drug prices. Innovation will be rewarded and cost savings achieved

ifproducers are allowed to

recoup research investments early in aproduct's life cycle in exchange for tighter controls later.
In addition, the encouragement o
fpolicies that create greater access to treatments so doctors and
physicians, not government bureaucrats, are making treatment decisions should be emphasized
and strengthened

Ms. Burdsy admits that some individuals are existing in a "crisis mode," however, price hikes arc
necessary. Crisis, as she states, is in the "eyes of the beholder."

Ms. Burdsy states that the use of price

caps will have a negative effect upon research and development and will cause restricted access to new
therapies. The items that a federa1 drug policy must include, says Ms. Burdsy, is an encouragement to
invest in research and rewards innovation and cost control. Ms. Burdsy's opinions are in line with my own,
supporting my stance that there does not exists a wide-spread crisis concerning phannaceutical costs. and
that caps are not an acceptable answer.

Next, we look at the response of Dr. Raul Abad, V.P. Medical Affairs:
I. Do you believe that there does or docs not exist a state of crisis regarding prescription drug prices and
their effects upon those on a fixed income? Why or Why Not?
Yes, there is a crisis. Theprices kee
p going up and the average income. especially elderly,
remains the same. M
any more drugs are being prescribed and patients have to get what has been
prescribedfor them.

2. If "Ycs, you do believe there exists a crisis," what do you believe is the main contributor, the
Phannaceutical industry seeking to maximize profits, or the current lack of a Federal policy to regulate
prices?
Primary is the pharmaceutical industry seeking to maximize profits. Secondary is the geMric
medications that are sometimes not really the same as what was ordered.

3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon
Phannaceutical industry investment in research and development? Why or Why Not?
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Yu, it would have a negative effect becawe It will cut baclc on the capital available f
or ruearch.
Thefirst thing that ts CUI is always research and development.

4. In your opinion, what is the single most important

i
tem

a government policy on prescription drug prices

must contain?

The Federal govemmenJ would impose a certain percefllage on the base price marhq,, no/
necessarily a cap to only charge certain amounJs. Also, utilize a certain percentage for research
and development.

Dr. Abad supports the stance that there does exist a crisis. Perhaps this is because, in his past experience as
a practicing neurosurgeon, he has been involved with first-hand situations of patients unable to afford
prescriptions.

He does; however, agree that price caps and restrictions are not the answer. His suggested

policy using profit percentage caps is interesting. This is similar to the utility industry, where profits are
held in line in such a way. Perltaps this could be a viable option, but only if the industry itself is allowed to
participate in the setting of such percentages. Otherwise, I believe they will have the same negative effects
as outright price capping.

The next questionnaire contains the responses of Dr. Veronica Santilli.
I. Do you believe that there does or does not exist a state of crisis regarding prescription drug prices and
their effects upon those on a fixed income? Why or Why Not?

B
y and large, there really is no crisis regarding prescription drug prices. There are those, however, who
would lilce the government to provide prescription benefits to Medicare patients and have exaggerated the
inability o
fthose onfu:ed incomes to access the drugs they need. My reasons are asfollows:
•

All Medicare patienJs have the option to opt for Medicare Managed Care Plan, which provides an

•

M
any states haveprescription plans, which senior citizens can participate in/or a small premium.

allowance for prescription drugs.

In N
ew Yorlc State, senior citizens can subscribe f
or the Epic Program, through which prescription
drugs can be obtainedfor small or no co-pays.
•

Truly indigent patienJs are eligible for Medicaid coverage in addition to Medicare. These patients
do not payf
or drugs.

•

Physicians always have samples in o
ff
ice that they give free o
fcharge to those without
prescription coverage.

•

Generic prescription drugs, which are comparable to brand names, can be obtained at reduced
cost.

•

Several senior citizens onf,xed incomes have ability to access their drugs through wholesale
pharmacy concerns/or small service charges through their union or as part o
f their retirement
benefits.

2. If "Yes, you do believe there exists a crisis," what do you believe is the main contributor, the
Pharmaceutical industry seeking to maximize profits or the current lack of a Federal policy to regulate
prices?

Those who believe that there is an existing prescription drug crisis for suiiors onfixed incomes are mainly
concerned with the laclc o
ffederal regulation o
f drug prices and laclc o
fprescription drugs as part o
f the
benefit package o
fMedicare.
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3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon
Phannaceutical industry investment in research and development? Why or Why Not?

1 absolutely believe that any cap or other regidalory activity on prescription drug prices defmitely will
thwart the research into and development o
f new drugs. Pharmaceutical companies an: primarily
interested in profits. These profits are distributed to stockholders inpart, but much o
f these proflls are put
back into new drug research. i
t is more important to urge the pharmoceuJlcal companies to develop
voluntary programs (grants), which would allow qualified patients to receive company sponsored discounls
on drugs. in additions the companies can pruvide vouchers, which could be distributed through providers
o
fhealth services, senior centers andpharmacies. Thef
eder
al government should urge andfacilitate the
development o
f quality generic drug substitutes and encourage physicians to prescribe these, when
feasible.

4. In your opinion, what is the single most important item a government policy on prescription drug prices
must contain?

The most important item, which any government policy on prescription dru
gs needs to contain, is the Drug

companies, which can demonstrate that they are willing to work with consumers, directly or through state
subsidized prescription programs, should be given recognition through tax relief, special creaJion o
fa
system which provides f
or greater competition among producers o
fpharmaceutical, consideration by the
FDA and recognition for their humanitarian activities.

Dr. Santilli supports my opinion that there does not exist a state of crisis. I was surprised at this, believing
that she would share the stance of fellow physician, Dr. Abad, due to her first hand experience with
patients. Her answer to question three is quite interesting, specifically in her suggestions that
phannaceutical companies take on a voluntary stance on price discounting and her thoughts on the
government promotion of generic drug production.

The following are the responses submitted on behalf of the Cedar Grove Mayor, Mr. Joseph Torlucci:
l. Do you believe that there does or does not exist a state of crisis regarding prescription drug prices and
their effects upon those on a fixed income? Why or Why Not?
I do believe there is a state o
f crisis regarding prescription dn,g prices .... ] base this
determination on personal knowledge with family, including 2 elderly parents.

2. lf "Yes, you do believe there exists a crisis," what do you believe is the main contributor, the
Phannaceutica1 industry seeking

to

maximize profits, or the current lack of a Federal policy to regulate

prices?
I do not necessarily believe that the industry tries to "maximize profits"· yet there certainly is a
needfor more governmental intervention.

3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon
Phannaceutical industry investment in research and development? Why or Why Not?
Caps,

ifnot reasonably set - certainly will curtail R &: D.

4. In your opinion, what is the single most important item a government policy on prescription drug prices
must contain?
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Permitting a dru
g company to extend patents on drug
s in �hangefor creating cost controls to
t
he benefit o
fcomumers.

The responses ofMayor surprised me. As a politician, I thought there would be support for increased
government intervention; However, a very interesting

i
dea

was his patent extension grant in return for the

industry to cut its own costs. I can see where this would serve as a great incentive f
or cuts - it gives the
industry two things: the patents

i
t

needs to maximize their profits longer on individual products as well as

an opportunity for implementing a cost program themselves. This strikes me as a rather mild form of
intervention worth looking into further.

Representatives O' Toole and Pascrell chose not to participate in this project After first contacting them
by mail, then later by phone, both offices refrained from providing comments on this issue.

Perhaps due to

its controversial nature and the timelines of the politics involved, there was some f
ear that providing formal
responses could come back and haunt them. This was quite disappointing. Their comments would have
been interesting and important, giving insight into the politics behind my topic. The responses of the Mayor
of Cedar Grove did; however, show me a bit of this.

To conclude, I had thought prior to receiving the completed questionnaires, that there would be less
agreement in the responses. I had expected that the pharmaceutical representative would fall to the left side,
denying any crisis, and that the politicians would fall to the far right, claiming the existence of an extreme
crisis, blaming the pharmaceutical industry. I also thought the physicians would fall somewhere in between.
Looking at the opinions, there is no extreme left or right.

It is important to note that each interviewee; although approaching the questions from varying
perspectives, all agree that caps on pharmaceutical prices arc not the answer to the problem of high costs.
All agree that this would do more harm than good, negatively affecting research and development.
There is disagreement on the existence or level of crisis; however, each provides interesting ideas as to
what

fu
ture

legislation must include in order to be effective. Overall, I was quite satisfied with the results of

this partofmy study.
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Closing Notes
The media coverage and the statistics out there tell us that there exists a crisis in this country concerning
the high cost of prescription prices on those on a fixed income. The industries and politicians argue back
and forth as to why and how great. By looking at my sample, one really cannot soc: a crisis. If this sample is
a fairly good representation of the population of this country, then perhaps the crisis is not as great as we're
led to believe. I do think that this is a good representation of the high population, suburban, Northeast
portion of the United States. Any future studies into this situation must use a sample similar to mine - one
that is suburban and as "average" as possible.

Using lower-income, inner city or too affluent a sample

would generate unrealistic, skewed data. It would be interesting to sample similar populations from varying
regions of the country to compare and contrast the data for more complete conclusions.

I do think that this

study was weak due to its limit to one sample.
As generations become less dependent upon Social Security for their retirement and also are more open to

less costly managed care programs, I believe the "crisis" perceived will lessen.
are not the answer.

Price caps and restrictions

By tying the hands of industry, inevitably it is the consumer who will suffer. Cut the

profits for the phannaceutical industry and they will answer with a cut to research and development as well
as the production of drugs for less-profitable and more rare conditions.
Certainly, there are areas that need improvement, and everyone would benefit from some sort of policy
change concerning certain costs of medications. By looking at this simple survey, the results show us an
important fact, namely that many of those falling into this age group suffer from the same conditions.
Therefore, any future policy should focus upon these conditions. Why couldn't a plan support subsidies for
high blood pressure and arthritis's medications? Or, perhaps there could be a subsidy plan that uses a scale
approach covering more for common- ailment prescriptions and scaling down for lesser. Answers can be
found that are more industry-friendly. In the writing of future policy, it would be in the best interest of all
parties if it were co-written by three parties - the Federal government, the AARP and a representative board
from the pharmaceutical industry. Any policy writing that shuts out the pharmaceutical industry or a body
representing the elderly would generate regulations that would damage both groups.
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EXHIBIT 1

Geographic Sample Area Demographics
Cedar Grove, New Jersey
(1990 U.S. Census Data)

Population (1996 estimate):

11,731

Race:
White:

94.62%

African American:

2.32%

Other:

3.08%

Median Age:

41.80 Years

65 and Older:

21.23%

Number of Households with persons over 65:

1,361

Number of Households Receiving Social Security:

1,351

Per Capita Income:

$23,052

Median Household Income:

$55,464

Number of Persons in Poverty:

Median Value of a Single Family Home:

332

$213,300
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EXHIBITS

Justine Maiello
Seton Hall University
Capstone Project: Survey of the impact of increased pharmaceutical costs on

retirees on a fixed income

This survey is anonymous and confidential. Feel free to skip any question
that you do not feel comfortable answering.

I. What is your Age?

___Years

2. Sex:

3 . How many years have you been retired?

M/F

Years

----

4. How long have you lived in this community?

----

Years

5. For what condition(s) do you regularly take a prescription medication?
Please circle all that apply: Diabetes
High Blood Pressure
Heart Ailments
Arthritis

Depression
Glaucoma
Other (please specify)

_

6. Have you had any of the following chronic diseases:
Please circle all that apply: Cancer
Heart Disease
Respiratory Disease
Arthritis
Stroke
Glandular Disorders
Other (please specify)

7. Do you participate in
(please circle one)

A.)Traditional Medicare

_

or B.)Medicare HMO

8. Why did you choose the plan selected in question #7?

9. Do you have a private Medigap policy?

YES I NO

10.lfyou chose "YES" for question #9, what are you currently paying for it?

$

/month

11.Ifyou chose "YES" for question #9, why did you choose to participate in

Medigap?

_

12.Have you ever not filled a prescription due to its cost?

YES

I NO

13. Have you ever rationed your medication to make your prescription last
longer due to its cost?

YES

I NO

14. Have you ever postponed paying bills or reducing food outlays due to
the cost of your medications?

YES

I NO

Thank you for your participation. If you could please return this survey in

the attached postage-paid envelope by May 30, 2001

